Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsten Stollhoff

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
MMW Fortschritte Der Medizin|November 16, 2023
[ADHD during adolescence - lost in transition]Kirsten Stollhoff
Postgraduate Medicine|September 10, 2011
Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPHAndreas Kordon, Kirsten Stollhoff, Käte Niederkirchner, et al.
Attention Deficit and Hyperactivity Disorders|March 25, 2011
Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trialMartin Gerwe, Kirsten Stollhoff, Jacek Mossakowski, et al.
Attention Deficit and Hyperactivity Disorders|March 25, 2011
A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeksEberhard Schulz, Christian Fleischhaker, Klaus Hennighausen, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
MMW Fortschritte Der Medizin|November 16, 2023
[ADHD during adolescence - lost in transition]Kirsten Stollhoff
Postgraduate Medicine|September 10, 2011
Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPHAndreas Kordon, Kirsten Stollhoff, Käte Niederkirchner, et al.
Attention Deficit and Hyperactivity Disorders|March 25, 2011
Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trialMartin Gerwe, Kirsten Stollhoff, Jacek Mossakowski, et al.
Attention Deficit and Hyperactivity Disorders|March 25, 2011
A randomized, rater-blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention-deficit hyperactivity disorder under different breakfast conditions over 2 weeksEberhard Schulz, Christian Fleischhaker, Klaus Hennighausen, et al.
Pageof 1